Skip to main content

Time to Challenge Current Strategies for Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma

Digestive Diseases and Sciences volume 65, pages 18–21 (2020)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Notes

  1. American Cancer Society. Facts and Figures 2019. American Cancer Society. Atlanta, Ga. 2019.

  2. https://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=8&pageSEL=sect_08_table.22.

  3. https://www.aamc.org/data/workforce/resources.

References

  1. Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012;7:443–447.

    Article  Google Scholar 

  2. Tramontano AC, Sheehan DF, Yeh JM, et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am J Gastroenterol. 2017;112:1256–1264.

    Article  Google Scholar 

  3. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.

    Article  Google Scholar 

  4. Visrodia K, Singh S, Krishnamoorthi R, et al. Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2016;44:775–784.

    CAS  Article  Google Scholar 

  5. Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.

    Article  Google Scholar 

  6. Sawas T, Killcoyne S, Iyer PG, et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology. 2018;155:1720–1728. (e1724).

    Article  Google Scholar 

  7. Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594–602. (discussion 601-592).

    Article  Google Scholar 

  8. Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2019;17:864–868.

    Article  Google Scholar 

  9. Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2015;150:599–607.

    Article  Google Scholar 

  10. Gaddam S, Singh M, Balasubramanian G, et al. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013;145:548–553. (e541).

    Article  Google Scholar 

  11. Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1046–1055. (e1048).

    Article  Google Scholar 

  12. Asge Standards of Practice C, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359. (e332).

    Article  Google Scholar 

  13. Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76:531–538.

    Article  Google Scholar 

  14. Rubenstein JH, Thrift AP. Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:41–50.

    Article  Google Scholar 

  15. Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945–953. (e942).

    Article  Google Scholar 

  16. Honing J, Kievit W, Bookelaar J, Peters Y, Iyer PG, Siersema PD. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett’s esophagus in patients with GERD symptoms. Gastrointest Endosc. 2018;89:712–722.

    Article  Google Scholar 

  17. Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110:148–158.

    Article  Google Scholar 

  18. Gora MJ, Sauk JS, Carruth RW, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med. 2013;19:238–240.

    CAS  Article  Google Scholar 

  19. Mallick R, Patnaik SK, Wani S, Bansal A. A systematic review of esophageal MicroRNA markers for diagnosis and monitoring of Barrett’s esophagus. Dig Dis Sci. 2016;61:1039–1050. https://doi.org/10.1007/s10620-015-3959-3.

    CAS  Article  PubMed  Google Scholar 

  20. Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:2241–2255. (e2244).

    CAS  Article  Google Scholar 

  21. Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67:1942–1949.

    CAS  Article  Google Scholar 

  22. Elliott DRF, Walker AW, O’Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol. 2017;2:32–42.

    Article  Google Scholar 

  23. Januszewicz W, Tan WK, Lehovsky K, et al. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients. Clin Gastroenterol Hepatol.. 2019;17:647–656. (e641).

    Article  Google Scholar 

  24. Gharahkhani P, Fitzgerald RC, Vaughan TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016;17:1363–1373.

    Article  Google Scholar 

  25. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52. (quiz e13).

    Article  Google Scholar 

  26. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. (quiz 51).

    CAS  Article  Google Scholar 

  27. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.

    Article  Google Scholar 

  28. Sawas T, Manrique GC, Iyer PG, Wang KK, Katzka DA. Young adults with esophageal adenocarcinoma present with more advanced stage tumors and have shorter survival times. Clin Gastroenterol Hepatol. 2019;17:1756–1762.

    Article  Google Scholar 

  29. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).

    Article  Google Scholar 

  30. Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal caner. J Gastrointest Oncol. 2012;3:226–231.

    PubMed  PubMed Central  Google Scholar 

  31. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–358.

    Article  Google Scholar 

  32. Fang TC, Oh YS, Szabo A, Khan A, Dua KS. Utility of dysphagia grade in predicting endoscopic ultrasound T-stage of non-metastatic esophageal cancer. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2015;29:642–648.

    Article  Google Scholar 

  33. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo 9, Mayo Clinic, 200 First Ave., S.W., Rochester, MN, 55905, USA

    David A. Katzka

  2. Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge, UK

    Rebecca C. Fitzgerald

Authors
  1. David A. Katzka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca C. Fitzgerald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Katzka.

Ethics declarations

Conflict of interest

DAK was involved in Research funding Shire, Honorarium Celgene, and RCF was listed as an inventor on patents pertaining to Cytosponge and associated assays which have been licensed by the Medical Research Council to Medtronic.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Katzka, D.A., Fitzgerald, R.C. Time to Challenge Current Strategies for Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci 65, 18–21 (2020). https://doi.org/10.1007/s10620-019-05965-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05965-0